Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05470933
Other study ID # JS124-001-I
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date August 23, 2022
Est. completion date April 18, 2023

Study information

Verified date August 2023
Source Suzhou Junjing BioSciences Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase I study to Investigate the safety and tolerability, DLT(Dose limited toxicity), MTD(Maximum tolerated dose), and RP2D(Recommended phase II dose) of WJ01075 tablets in patients with advanced malignant solid tumors, including phase Ia (dose escalation phase) and Phase Ib (dose expansion phase,cohort expansion phase).The study includes screening, treatment and follow-up periods. In phase Ia, accelerated titration (the first two dose groups) and "3 + 3" combination (the subsequent dose group) were used for dose escalation. In phase Ib, specific dose groups will be selected for dose expansion according to PK(Pharmacokinetics) and safety data of different dose groups in dose escalation phase.It is planned that SMC(Safety Monitoring Committee) will select one or more dose groups based on previous data for cohort expansion studies to further determine RP2D, safety tolerability and initial efficacy.


Recruitment information / eligibility

Status Terminated
Enrollment 7
Est. completion date April 18, 2023
Est. primary completion date April 18, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Patient with advanced malignant solid tumors clearly diagnosed pathologically and/or cytologically, who have failed to receive standard treatment, or who currently do not/or refuse standard treatment, or who are intolerant to standard treatment; 2. Patient must have at least one measurable lesion as defined per RECIST v1.1; 3. Aged between 18 and 75 (including 18 and 75), male and female patients; 4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score =1; 5. Life expectancy = 3 months; 6. The functions of patients' major organs were basically normal, and the laboratory tests performed within 7 days prior to the first administration of study drugmet the following criteria, Patients must not have required a blood transfusion or growth factor support within 14 days before the examination: Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) =2.5 × Upper limit of Normal (ULN); Total Bilirubin= 1.5×ULN; International Normalized Ratio (INR) =1.5; Creatinine = 1.5 × ULN, and Creatinine Clearance Rate (calculated by Cockcroft-Gault formula) = 50 mL/min; Hemoglobin (Hg) = 90g/L; Platelets = 100×10?9/L; Absolute Neutrophil Count(ANC) = 1.5×10?9/L 7. Fertile women must confirm a negative blood pregnancy test within 7 days prior to the first administration of study drug;All enrolled patients (both male and female) are required to use adequate and effective contraceptive measures throughout the treatment period and within 3 months after the end of treatment; 8. Those who voluntarily participate in the study and sign the written Informed Consent Form upon full informed consent. Exclusion Criteria: 1. Prior treatment with XPO1 inhibitors; 2. Have a history of allergy to any component or excipient of WJ010175 tablets; 3. Patient with a primary malignancy other than the tumor treated in the study within 5 years prior to the first administration of study drug (exceptions include cured malignancies that did not recur within 3 years prior to enrollment;Basal cell and squamous cell carcinoma completely resected;Complete excision of any type of carcinoma in situ, etc.); 4. Received other anti-tumor therapies, including but not limited to chemotherapy, radiotherapy, targeted therapy, immunotherapy and other anti-tumor therapies (such as anti-tumor traditional Chinese medicine), within 4 weeks or 5 half-life periods (whichever is longer) prior to the first administration of study drug;Or long-term treatment with potent CYP1A2 inhibitors, potent CYP3A4 inducers and potent CYP3A4 inhibition; 5. Thrombosis or embolism occurred within 6 months prior to the first administration of study drug; 6. Received medium or major surgical treatment within 4 weeks prior to the first administration of study drug, other than diagnostic biopsy ; 7. Any of the following conditions within 6 months prior to the first administration of study drug: New York Cardiology Association (NYHA) > Grade II cardiac insufficiency, congestive heart failure, severe/unstable angina pectoris (symptoms of resting angina pectoris), myocardial infarction, arrhythmias requiring treatment, uncontrolled hypertension or hypertensive crisis or hypertensive encephalopathy; 8. Adverse events and/or complications caused by previous treatment are not relieved to < Level 2 (per NCI-CTCAE V5.0);Any level of hair loss/pigmentation and long-term toxicity caused by other treatment, other than those that the investigator diagnosiss cannot be recovered and do not affect study administration or compliance and patient safety; 9. Patient with central nervous system metastasis or tumors originating in the central nervous system;, 10. Patient with grade = 2 neuropathy (per NCI-CTCAE V5.0); 11. Severe infections requiring antibiotic treatment within 14 days prior to the first administration of study drug ( > CTCAE Grade 2 ), such as severe pneumonia, bacteremia, infection complications requiring hospitalization; 12. Uncontrolled pericardial effusion, pleural effusion or clinically obvious moderate to severe abdominal effusion during screening is defined as meeting the following criteria: having clinical symptoms and detectable thoracic and abdominal effusion during physical examination;Or in the screening process, the thoracoabdominal effusion needs to be punctured pumping liquid and/or intravenously administered; 13. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; 14. Patient has serious psychological or mental abnormalities affecting the compliance of the subjects to participate in the study; 15. With active Hepatitis B, or Hepatitis C, or Human Immunodeficiency Virus positive [HIV (+)] and syphilis antibody (+);Note: Hepatitis B virus surface Antigen (HBsAg) or core antibody (HBcAb) positive should be tested for HBV-DNA, and HBV-DNA should be below the lower limit of the reference range.Patients who are positive for Hepatitis C virus Antibody (HCV Ab) will be tested for HCV RNA and can be enrolled if they are below the upper limit of normal. 16. With Gastrointestinal dysfunction that may affect drug absorption (e.g., intestinal obstruction, inability to swallow tablets, malabsorption syndrome, uncontrollable nausea or vomiting, etc.); 17. Pregnant or lactating women or men who still have reproductive needs; 18. Other conditions that the investigator considers to be ineligible for inclusion, including but not limited to subjects whose body weight is less than ideal and who are expected to be significantly affected by weight change as determined by the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
WJ01075
Phase Ia: Dose Escalation Accelerated titration (the first two dose groups) and "3 + 3" combination (the subsequent dose group) were used for dose escalation. Phase Ib: Dose Expansion and Cohort Expansion The actual dose, dosing schedule (including combination) and indication selection will be evaluated based on the results of existing trials.

Locations

Country Name City State
China Harbin Medical University Cancer Hospital Harbin Heilongjiang

Sponsors (1)

Lead Sponsor Collaborator
Suzhou Junjing BioSciences Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose limited toxicity (DLT) incidence and severity of Dose limited toxicity(DLT); 3 years
Primary Adverse event (AE) incidence and severity of adverse event (AE), Abnormal changes in laboratory and other tests of clinical significance; 3 years
Primary Serious adverse event (SAE) incidence and severity of Serious adverse event (SAE); 3 years
Primary Maximum tolerated dose (MTD) Maximum tolerated dose (MTD) 2 years
Primary Recommended phase II dose (RP2D) Recommended phase II dose (RP2D) 2 years
Secondary Objective response rate(ORR) Efficacy endpoints: Objective response rate(ORR) per RECIST v1.1 2 years
Secondary Duration of response (DOR) Efficacy endpoints: Duration of response (DOR) per RECIST v1.1 2 years
Secondary Disease control rate (DCR) Efficacy endpoints: Disease control rate (DCR) per RECIST v1.1 2 years
Secondary Time to response(TTR) Efficacy endpoints: Time to response(TTR) per RECIST v1.1 2 years
Secondary Progression-free survival (PFS) Efficacy endpoints: Progression-free survival (PFS) per RECIST v1.1 2 years
Secondary Overall survival (OS) Efficacy endpoints: Overall survival (OS) per RECIST v1.1 2 years
Secondary Peak time(Tmax) Pharmacokinetic (PK) parameter : Peak time(Tmax) after a single dose; 2 years
Secondary Maximum plasma concentration (Cmax) Pharmacokinetic (PK) parameter : Maximum plasma concentration (Cmax) after a single dose; 2 years
Secondary Clearance rate (CL/F) Pharmacokinetic (PK) parameter : Clearance rate (CL/F) after a single dose; 2 years
Secondary Apparent volume of distribution (Vd/F) Pharmacokinetic (PK) parameter : Apparent volume of distribution (Vd/F) after a single dose; 2 years
Secondary Area under blood concentration - time curve (AUC) Pharmacokinetic (PK) parameter : Area under blood concentration - time curve (AUC) after a single dose; 2 years
Secondary Elimination rate constant (?z) Pharmacokinetic (PK) parameter : Elimination rate constant (?z) after a single dose; 2 years
Secondary Elimination half-life time ( t1/2) and other parameters Pharmacokinetic (PK) parameter : Elimination half-life time ( t1/2) and other parameters after a single dose; 2 years
Secondary Steady state valley concentration(Cssmin) Pharmacokinetic (PK) parameter : Steady state valley concentration(Cssmin) after repeated administration; 2 years
Secondary Steady state peak concentration(Cssmax) Pharmacokinetic (PK) parameter : Steady state peak concentration(Cssmax) after repeated administration; 2 years
Secondary Average steady-state plasma concentration(Css-av) Pharmacokinetic (PK) parameter : Average steady-state plasma concentration(Css-av) after repeated administration; 2 years
Secondary Elimination half-life time ( t1/2) Pharmacokinetic (PK) parameter : Elimination half-life time ( t1/2) after repeated administration; 2 years
Secondary Steady state Area under blood concentration - time curve(AUCss) Pharmacokinetic (PK) parameter : Steady state Area under blood concentration - time curve(AUCss) after repeated administration; 2 years
Secondary Fluctuation coefficient (DF) Pharmacokinetic (PK) parameter : Fluctuation coefficient (DF) after repeated administration; 2 years
Secondary Steady-state distribution volume(Vss ) Pharmacokinetic (PK) parameter : Steady-state distribution volume(Vss ) after repeated administration; 2 years
Secondary Accumulation coefficient (AR) and other parameters Pharmacokinetic (PK) parameter : Accumulation coefficient (AR) and other parameters after repeated administration; 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04972981 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors Phase 1
Completed NCT05086822 - A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors Phase 1
Completed NCT03260322 - A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Phase 1
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT06040541 - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors Phase 1
Recruiting NCT05862831 - Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT03641794 - Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers Phase 1
Terminated NCT03665129 - IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Recruiting NCT05914116 - A Study of DB-1311 in Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT01693562 - A Phase 1/2 Study to Evaluate MEDI4736 Phase 1/Phase 2
Recruiting NCT04387916 - A Study of KC1036 in Patients With Advanced Solid Tumors Phase 1
Completed NCT04095273 - Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Phase 1
Not yet recruiting NCT03692520 - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors Phase 1
Completed NCT02997176 - An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) Phase 1
Recruiting NCT04446260 - A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT02253992 - An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2
Recruiting NCT06076291 - An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT03545971 - A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors. Phase 1